- Eli Lilly’s rheumatoid arthritis drug baricitinib, sold under the brand name Olumiant, prevented 1 death for every 6 patients on a ventilator in a phase 3 clinical trial.
- The FDA revised its emergency use authorization for Regeneron’s COVID-19 antibody cocktail of casirivimab and imdevimab, allowing the treatment to be used as a post-exposure prophylaxis for COVID-19 in individuals who are at high risk for progression to severe COVID-19.
- Bamlanivimab or casirivimab-imdevimab, two monoclonal antibodies, were effective in preventing hospitalization among high-risk patients with COVID-19 when administered separately in a real-world study.
- Gilead’s remdesivir may be associated with longer hospital stays for COVID-19 patients, even after they have recovered, so that they can finish the treatment course, a study suggested.
- The antibiotic azithromycin didn’t reduce the risk of hospitalization, respiratory failure or death in COVID-19 patients in a clinical trial.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
